13F Holdings
中文EN

Versant Venture Management, LLC

San Francisco CA · SEC CIK 0001560009

2026Q22026Q1 9 earlier quarters 🔒
$162.61M2026Q2 reported value
8Positions
100.0%Top 10 weight · largest 47.3%
0 / 0New / sold out
Reported value over time$162.61M2026Q2
26Q126Q2

All 11 quarters on paid plans 🔒

Top 10 holdings % of portfolio

GLUE 47.3%
IPSC 18.3%
JBIO 13.6%
LENZ 9.3%
CTNM 5.5%
CRSP 5.0%
Skye Bioscienc 0.9%
Tempest Therap 0.2%

2026Q2 top buys estimated at quarter-end value

No buys this quarter

2026Q2 top sells estimated at quarter-end value

JBIO Reduced-$11.87M

2026Q2 holdings click a header to sort

Export CSV 🔒
TickerNameValue ▼WeightSharesShare changeChangeEst. flowAction
GLUE Monte Rosa Therapeutics, Inc. $76.97M47.34%3,180,780 00.0% — Unchanged
IPSC Century Therapeutics, Inc. $29.81M18.33%12,166,109 00.0% — Unchanged
JBIO Jade Biosciences, Inc. $22.04M13.55%991,783 -534,037-35.0% -$11.87M Reduced
LENZ Lenz Therapeutics, Inc. $15.09M9.28%2,656,888 00.0% — Unchanged
CTNM Contineum Therapeutics, Inc. $8.89M5.47%542,628 00.0% — Unchanged
CRSP CRISPR Therapeutics AG $8.12M4.99%148,831 00.0% — Unchanged
— Skye Bioscience, Inc. $1.39M0.86%2,007,704 00.0% — Unchanged
— Tempest Therapeutics, Inc. $299,4470.18%269,772 00.0% — Unchanged